AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10769856 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnograph monitoring
Number of subjects: 22
Study 9239770 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV and PedvaxHIB given concurrently
Number of subjects: 294
Study 9239770 — intervention group
Group type: COMPARATOR
Intervention: M-M-R II and PedvaxHIB followed by VARIVAX 6 weeks later
Number of subjects: 294
Study 8396101 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day for three days)
Number of subjects: 389
Study 8396101 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (13.3 mg/kg tid for ten days)
Number of subjects: 389
Study 2939870 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 11.3 mg once daily
Number of subjects: 172
Study 2939870 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 13.8 mg twice daily
Number of subjects: 172
Study 2939870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 2939870 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin, Prazosin, and Placebo
Number of subjects: 172
Study 2939870 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 172
Study 31675478 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-water (290 mL)
Number of subjects: 14
Study 29405233 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenezumab (anti-amyloid-β antibody)
Number of subjects: 252
Study 29405233 — intervention group
Group type: COMPARATOR
Intervention: Pre-screening process
Number of subjects: 252
Study 25864681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol-based adhesive bond (ExciTEF, Ivoclar Vivadent) applied prior to sealant application
Number of subjects: 112
Study 25864681 — intervention group
Group type: COMPARATOR
Intervention: No bonding agent used
Number of subjects: 112
Study 25864681 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's behaviour
Number of subjects: 112
Study 25338555 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour at 41 + 0/+1 weeks
Number of subjects: 0
Study 25338555 — intervention group
Group type: COMPARATOR
Intervention: Expectant management until 42 weeks
Number of subjects: 0
Study 24305423 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen plus ultraviolet A (PUVA)
Number of subjects: 20
Study 24305423 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B (NB-UVB)
Number of subjects: 20
Study 24305423 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study 20605760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery followed by chemotherapy
Number of subjects: 0
Study 20605760 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial assay of serum CA-125
Number of subjects: 0
Study 20605760 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent research protocols
Number of subjects: 0
Study 18217460 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine before operation
Number of subjects: 91
Study 18217460 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral clonidine before operation
Number of subjects: 91
Study 18217460 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine at the end of the operation
Number of subjects: 91
Study 18217460 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline before operation
Number of subjects: 91
Study 15277154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet (LGI)
Number of subjects: 45
Study 15277154 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic-index diet (HGI)
Number of subjects: 45
Study 11207173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-osmolar ORS (224 mmol/l)
Number of subjects: 64
Study 11207173 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS (311 mmol/l)
Number of subjects: 64
Study 10453599 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage treatment for recurrent respiratory tract infection; details on dosage and duration not specified.
Number of subjects: 0
Study 10453599 — intervention group
Group type: COMPARATOR
Intervention: Control group (susceptible and healthy children); details on treatment not specified.
Number of subjects: 0
Study 7872728 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-alpha expression in lung carcinomas
Number of subjects: 51
Study 7872728 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-alpha expression
Number of subjects: 51
Study 3207146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive skills remediation
Number of subjects: 0
Study 3207146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive skills and ADL remediation program
Number of subjects: 0
Study 30368472 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT) in patients LSW >6 hours
Number of subjects: 752
Study 30368472 — intervention group
Group type: COMPARATOR
Intervention: Mechanical Thrombectomy (MT) in patients LSW <6 hours
Number of subjects: 752
Study 29635505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact whey protein (15 g)
Number of subjects: 11
Study 29635505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein (15 g)
Number of subjects: 11
Study 29635505 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study 27569684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion (hyperinsulinemic-euglycemic-clamp)
Number of subjects: 34
Study 27569684 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline infusion (control group)
Number of subjects: 34
Study 27569684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both insulin and saline infusion groups
Number of subjects: 34
Study 24865978 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric acupoint stimulation
Number of subjects: 72
Study 24865978 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 72
Study 22927555 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 6505
Study 22927555 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6505
Study 20707826 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visiting intervention for depressed mothers and their infants
Number of subjects: 58
Study 20707826 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated mother-child dyads)
Number of subjects: 58
Study 17030438 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS on four acupuncture points (Hegu [Li 4] and Sanyinjiao [Sp 6])
Number of subjects: 105
Study 17030438 — intervention group
Group type: COMPARATOR
Intervention: TENS placebo
Number of subjects: 105
Study 17030438 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS group
Number of subjects: 105
Study 15869351 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 20
Study 15869351 — intervention group
Group type: COMPARATOR
Intervention: Matched control participants
Number of subjects: 20
Study 11919728 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (2 mg/kg/day for 5 days before transplantation)
Number of subjects: 156
Study 11919728 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Thymoglobulin, similar regimen)
Number of subjects: 156
Study 11919728 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 156
Study 11919728 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Thymoglobulin)
Number of subjects: 156
Study 10598762 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of soluble E-selectin (sE-selectin) in untreated PPP patients
Number of subjects: 30
Study 10598762 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of TNF-alpha in untreated PPP patients
Number of subjects: 30
Study 10598762 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between disease activity and serum levels of sE-selectin in untreated PPP patients
Number of subjects: 30
Study 10598762 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of sE-selectin in 10 PPP patients after treatment
Number of subjects: 30
Study 10598762 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity of PPP in smokers and during summer
Number of subjects: 30
Study 7547057 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) administered during operation
Number of subjects: 50
Study 7547057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1936753 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute administration of verapamil 160 mg
Number of subjects: 12
Study 1936753 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment of verapamil 240 mg/day for six months
Number of subjects: 12
Study 1936753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6755325 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria japonica
Number of subjects: 48
Study 6755325 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 31852502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (evidence-based groups delivered by trained staff)
Number of subjects: 120
Study 31852502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 27696633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (CSMT)
Number of subjects: 104
Study 27696633 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (sham push manoeuvre)
Number of subjects: 104
Study 27696633 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual pharmacological management)
Number of subjects: 104
Study 26432128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 0.1% and carboxymethylcellulose 0.5% artificial tears
Number of subjects: 282
Study 26432128 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid-antibiotic alone
Number of subjects: 282
Study 23567660 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum of 4 electrode pairs activated (Group 1)
Number of subjects: 120
Study 23567660 — intervention group
Group type: COMPARATOR
Intervention: Maximum of 2 electrode pairs activated (Group 2)
Number of subjects: 120
Study 23567660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 23567660 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 120
Study 23567660 — intervention group
Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 120
Study 21332825 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine (20 mg once daily)
Number of subjects: 567
Study 21332825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 19184182 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lead EKG
Number of subjects: 457
Study 19184182 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter studies
Number of subjects: 457
Study 19184182 — intervention group
Group type: COMPARATOR
Intervention: Risk factors
Number of subjects: 457
Study 19184182 — intervention group
Group type: COMPARATOR
Intervention: Umbilical venous lines and dopamine infusion
Number of subjects: 457
Study 18091666 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided‐tissue regeneration therapy (GTR) with scaling and root planing (SRP) and application of a bioresorbable membrane
Number of subjects: 11
Study 18091666 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 11
Study 15457806 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-digit load
Number of subjects: 0
Study 15457806 — intervention group
Group type: COMPARATOR
Intervention: no-load control
Number of subjects: 0
Study 11840580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg i.v.
Number of subjects: 135
Study 11840580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg i.v.
Number of subjects: 135
Study 11840580 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 135
Study 9500689 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (UDCA) 23-25 mg/kg/d
Number of subjects: 14
Study 9500689 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg/d
Number of subjects: 14
Study 9500689 — intervention group
Group type: COMPARATOR
Intervention: UDCA
Number of subjects: 14
Study 9500689 — intervention group
Group type: COMPARATOR
Intervention: simvastatin
Number of subjects: 14
Study 8919573 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 92
Study 8919573 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 92
Study 8919573 — intervention group
Group type: COMPARATOR
Intervention: Low dosage ECT
Number of subjects: 92
Study 8919573 — intervention group
Group type: COMPARATOR
Intervention: High dosage ECT
Number of subjects: 92
Study 8919573 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT course
Number of subjects: 92
Study 2186630 — intervention group
Group type: EXPERIMENTAL
Intervention: ancrod 0.5 mu/kg in normal saline administered as a constant-rate intravenous infusion over 6 hours
Number of subjects: 20
Study 2186630 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 20
Study 109596 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus 2.5 gm/kg of amino acids
Number of subjects: 0
Study 109596 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 0
Study 29188471 — intervention group
Group type: EXPERIMENTAL
Intervention: Brilliant Blue G (BBG)
Number of subjects: 117
Study 29188471 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan Blue (TB)
Number of subjects: 117
Study 29188471 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 117
Study 26063508 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2.4 mg once every 2 months + 10 μg daily for residents, 3 mg once every 2 months for carers
Number of subjects: 240
Study 26063508 — intervention group
Group type: COMPARATOR
Intervention: Placebo once every 2 months + vitamin D3 10 μg daily for residents, placebo once every 2 months for carers
Number of subjects: 240
Study 23860103 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electrical stimulation therapy
Number of subjects: 54
Study 23860103 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 54
Study 20451663 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg induction at weeks 0, 2, and 4; maintenance therapy randomized to every 2 weeks or every 4 weeks.
Number of subjects: 539
Study 20451663 — intervention group
Group type: COMPARATOR
Intervention: Certolizumab pegol 400 mg every 4 weeks maintenance therapy.
Number of subjects: 539
Study 20451663 — intervention group
Group type: COMPARATOR
Intervention: Certolizumab pegol 400 mg every 2 weeks maintenance therapy.
Number of subjects: 539
Study 20451663 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with certolizumab pegol.
Number of subjects: 539
Study 20451663 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy with certolizumab pegol.
Number of subjects: 539
Study 18771834 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard implementation intentions with protection motivation-based information
Number of subjects: 210
Study 18771834 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning implementation intentions with protection motivation-based information
Number of subjects: 210
Study 18771834 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation intentions without protection motivation-based information
Number of subjects: 210
Study 18771834 — intervention group
Group type: COMPARATOR
Intervention: Reasoning implementation intentions without protection motivation-based information
Number of subjects: 210
Study 16868453 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day
Number of subjects: 20
Study 16868453 — intervention group
Group type: COMPARATOR
Intervention: fluvastatin 80 mg/day
Number of subjects: 20
Study 12796126 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 150
Study 12796126 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 150
Study 12796126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 10666136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal fructose (25%)
Number of subjects: 10
Study 10666136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose (25%)
Number of subjects: 10
Study 10666136 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 10
Study 8852391 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 48
Study 8852391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1523108 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognitive theory AIDS prevention intervention
Number of subjects: 109
Study 6377803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 120 mg orally as 3 divided doses
Number of subjects: 60
Study 6377803 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 60
Study 31212365 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 125
Study 31212365 — intervention group
Group type: COMPARATOR
Intervention: 40 mg atorvastatin
Number of subjects: 125
Study 29425373 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program
Number of subjects: 450
Study 27529510 — intervention group
Group type: EXPERIMENTAL
Intervention: ALLN-177 treatment
Number of subjects: 30
Study 27529510 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 23952962 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (mixture of Bifidobacterium longum, Lactobacillus bulgaricus and Streptococcus thermophilus) three times per day for 4 weeks
Number of subjects: 65
Study 23952962 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral local antifungal agents alone: gargle 2% sodium bicarbonate solution for 30 s, wait 10 min and then apply 2% nystatin paste)
Number of subjects: 65
Study 22954164 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARK program
Number of subjects: 100
Study 22954164 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 20091310 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal repair with levatorplasty (TPR‐LP)
Number of subjects: 48
Study 20091310 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal repair without levatorplasty (TPR)
Number of subjects: 48
Study 20091310 — intervention group
Group type: COMPARATOR
Intervention: Transanal repair (TAR)
Number of subjects: 48
Study 17397435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desmopressin (ddAVP)
Number of subjects: 14
Study 17397435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17719472 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (10 to 20 mg/day)
Number of subjects: 22
Study 17719472 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (20 to 40 mg/day)
Number of subjects: 22
Study 14764771 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-rich diet
Number of subjects: 17
Study 10836283 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/day (days 1-4), 150 mg/day (days 5-10), 225 mg/day (days 11-42)
Number of subjects: 109
Study 10836283 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day (days 1-4), 40 mg/day (days 5-10), 60 mg/day (days 11-42)
Number of subjects: 109
Study 9096088 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m labelled monoclonal antibody (MAb) 170H.82 at protein doses of 1, 2 and 4 mg
Number of subjects: 53
Study 9096088 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m labelled monoclonal antibody (MAb) 170H.82 at 2 mg dose
Number of subjects: 53
Study 8362758 — intervention group
Group type: EXPERIMENTAL
Intervention: High counter height (35.5 inches) with near queuing area
Number of subjects: 42
Study 8362758 — intervention group
Group type: EXPERIMENTAL
Intervention: High counter height (35.5 inches) with far queuing area
Number of subjects: 42
Study 8362758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low counter height (31.5 inches) with near queuing area
Number of subjects: 42
Study 8362758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low counter height (31.5 inches) with far queuing area
Number of subjects: 42
Study 2938984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin acetate, D‐Nal(2)6‐GnRH, administered intranasally in a daily dose of 125 micrograms to 25 women.
Number of subjects: 47
Study 2938984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin acetate, D‐Nal(2)6‐GnRH, administered intranasally in a daily dose of 250 micrograms to 22 women.
Number of subjects: 47
Study 2938984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin acetate, D‐Nal(2)6‐GnRH, both doses (125 and 250 micrograms).
Number of subjects: 47
Study 30758167 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive neuro-stimulation (ANS) with 2 pre-set programs, 4 times a week using an ENF Physio® device (15-350 Hz)
Number of subjects: 20
Study 30758167 — intervention group
Group type: COMPARATOR
Intervention: Placebo (device switched off)
Number of subjects: 20
Study 30758167 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive neuro-stimulation (ANS)
Number of subjects: 20
Study 27651055 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcast learning
Number of subjects: 130
Study 27651055 — intervention group
Group type: COMPARATOR
Intervention: Text learning
Number of subjects: 130
Study 25031187 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (ICBT)
Number of subjects: 128
Study 25031187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (GCBT)
Number of subjects: 128
Study 25031187 — intervention group
Group type: COMPARATOR
Intervention: Web-based discussion forum (DF)
Number of subjects: 128
Study 24337491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography (DECT) with sagittal oblique displays (mixed kV soft tissue, SE bone removal, and DECT bone removal)
Number of subjects: 27